Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. The firm is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.
IXHL stock price ended at $0.29 on 金曜日, after rising 16.00%
On the latest trading day Feb 06, 2026, the stock price of IXHL rose by 16.00%, climbing from $0.26 to $0.29. Throughout the session, the stock experienced a volatility of 15.38%, with prices fluctuating between a daily low of $0.26 and a high of $0.30. Alongside this price increase, trading volume also rose by 1.1M shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 8.6M shares were traded, amounting to a market value of approximately $100.4M.